Guardant Health Inc
Company Profile
Business description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Contact
3100 Hanover Street
Palo AltoCA94304
USAT: +1 855 698-8887
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,021
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.10 | 2.30 | -0.03% |
| CAC 40 | 7,723.47 | 27.20 | 0.35% |
| DAX 40 | 24,073.67 | 286.22 | 1.20% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,806.53 | 16.38 | -0.19% |
| HKSE | 23,977.74 | 89.91 | 0.38% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,673.31 | 85.63 | 0.22% |
| NZX 50 Index | 12,745.90 | 19.05 | -0.15% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,584.50 | 4.80 | -0.06% |
| SSE Composite Index | 3,479.45 | 6.32 | 0.18% |